C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contractC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi. more ➔
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contractC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi. more ➔
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contractC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi. more ➔
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contractC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi. more ➔
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contractC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi. more ➔
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contractC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi. more ➔
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contractC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi. more ➔
Next-gen COVID-19 vaccine good in preclinical testsIntravacc has announced positive data for its nasal SARS-CoV-2 vaccine that embeds the viral spike antigen in bacterial Outer Membrane Vesicles (OMV) more ➔
EMA: AZD1222 causes serious rare ADEsIn a new statement, the EU regulatory authority EMA postulates that AstraZeneca’s vaccine causes serious deep vein thrombosis. more ➔
Targeting SARS-CoV-2 differentlyGerman structural biologists have identified seven compounds that neutralise SARS-CoV-2 by targeting Mpro, the virus’ main protease. more ➔
